ADMA Biologics Stock Buy Hold or Sell Recommendation

ADMA
 Stock
  

USD 3.36  0.13  4.02%   

Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding ADMA Biologics is 'Hold'. Macroaxis provides ADMA Biologics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ADMA positions. The advice algorithm takes into account all of ADMA Biologics' available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from ADMA Biologics' buy-and-hold perspective. Please continue to ADMA Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as ADMA Biologics and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards ADMA Biologics.

Execute ADMA Biologics Buy or Sell Advice

The ADMA Biologics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ADMA Biologics. Macroaxis does not own or have any residual interests in ADMA Biologics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ADMA Biologics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell ADMA BiologicsBuy ADMA Biologics
Hold

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Details

Financial Strenth (F Score)

Details

Financial Leverage

Inapplicable
Details

Reporting Quality (M-Score)

Details
For the selected time horizon ADMA Biologics has a Risk Adjusted Performance of 0.1403, Jensen Alpha of 0.2249, Total Risk Alpha of 0.1118, Sortino Ratio of 0.0926 and Treynor Ratio of 0.2016
We provide trade advice to complement the prevailing expert consensus on ADMA Biologics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available right now. To make sure ADMA Biologics is not overpriced, please confirm all ADMA Biologics fundamentals, including its shares owned by insiders, price to book, ebitda, as well as the relationship between the number of shares shorted and revenue . Given that ADMA Biologics has a price to earning of (1.55) X, we suggest you to validate ADMA Biologics market performance and probability of bankruptcy to ensure the company can sustain itself in the future given your prevailing risk tolerance and investing horizon.

ADMA Biologics Trading Alerts and Improvement Suggestions

ADMA Biologics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 80.94 M. Net Loss for the year was (71.65 M) with profit before overhead, payroll, taxes, and interest of 1.17 M.
ADMA Biologics currently holds about 52.42 M in cash with (112.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
ADMA Biologics has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Institutional investors are ADMA Biologics, Inc.s biggest bettors and were rewarded after last weeks US139m market cap gain - Simply Wall St

ADMA Biologics Returns Distribution Density

The distribution of ADMA Biologics' historical returns is an attempt to chart the uncertainty of ADMA Biologics' future price movements. The chart of the probability distribution of ADMA Biologics stock daily returns describes the distribution of returns around its average expected value. We use ADMA Biologics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ADMA Biologics returns is essential to provide solid investment advice for ADMA Biologics.
Mean Return0.44Value At Risk-5.47
Potential Upside7.20Standard Deviation4.88
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ADMA Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

ADMA Biologics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as ADMA Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADMA Biologics backward and forwards among themselves. ADMA Biologics' institutional investor refers to the entity that pools money to purchase ADMA Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares20.7 K50 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares20.7 K41 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares22 K40 K
Yintercept Hong Kong LtdCommon Shares48.3 K88 K
Yintercept Hong Kong LtdCommon Shares16.7 K27 K
Xtx Topco LtdCommon Shares21.3 K52 K
Xtx Topco LtdCommon Shares17.7 K20 K
Xr Securities LlcPut Options10 K11 K
Note, although ADMA Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ADMA Biologics Cash Flow Accounts

201720182019202020212022 (projected)
Capital Expenditure(2.68 M)(2.1 M)(3.81 M)(12.72 M)(13.51 M)(13.87 M)
Depreciation Amortization and Accretion2.69 M3.45 M3.26 M3.94 M5.5 M5.93 M
Net Cash Flow or Change in Cash and Cash Equivalents38.69 M(21.85 M)(2.72 K)29.17 M(4.83 M)(4.96 M)
Issuance Purchase of Equity Shares39.21 M42.96 M48.47 M131.21 M121.14 M130.71 M
Issuance Repayment of Debt Securities21.54 M(36.28 K)38.03 M13.52 M(34.3 K)(35.2 K)
Net Cash Flow from Financing60.75 M42.92 M80 M143.9 M121.05 M130.6 M
Net Cash Flow from Investing15.21 M(2.1 M)(3.81 M)(12.72 M)(13.51 M)(13.87 M)
Net Cash Flow from Operations(37.27 M)(62.68 M)(76.19 M)(102 M)(112.37 M)(115.33 M)
Share Based Compensation1.56 M2.22 M2.65 M2.86 M3.49 M2.81 M

ADMA Biologics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ADMA Biologics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ADMA Biologics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ADMA Biologics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
0.22
β
Beta against NYSE Composite2.14
σ
Overall volatility
4.81
Ir
Information ratio 0.07

ADMA Biologics Volatility Alert

ADMA Biologics shows above-average downside volatility for the selected time horizon. We advise investors to inspect ADMA Biologics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ADMA Biologics future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ADMA Biologics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ADMA Biologics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

ADMA Biologics Fundamentals Vs Peers

Comparing ADMA Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ADMA Biologics' direct or indirect competition across all of the common fundamentals between ADMA Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as ADMA Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ADMA Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare ADMA Biologics to competition
FundamentalsADMA BiologicsPeer Average
Return On Equity(0.69) %(0.31) %
Return On Asset(0.11) %(0.14) %
Profit Margin(0.54) %(1.27) %
Operating Margin(0.36) %(5.51) %
Current Valuation755.38 M16.62 B
Shares Outstanding196.78 M571.82 M
Shares Owned by Insiders2.01 %10.09 %
Shares Owned by Institutions79.95 %39.21 %
Number of Shares Shorted21.74 M4.71 M
Price to Earning(1.55) X28.72 X
Price to Book6.35 X9.51 X
Price to Sales5.07 X11.42 X
Revenue80.94 M9.43 B
Gross Profit1.17 M27.38 B
EBITDA(79.21 M)3.9 B
Net Income(71.65 M)570.98 M
Cash and Equivalents52.42 M2.7 B
Cash per Share0.27 X5.01 X
Total Debt94.87 M5.32 B
Debt to Equity1.32 %48.70 %
Current Ratio7.94 X2.16 X
Book Value Per Share0.51 X1.93 K
Cash Flow from Operations(112.37 M)971.22 M
Short Ratio6.76 X4.00 X
Earnings Per Share(0.49) X3.12 X
Target Price5.0
Number of Employees52718.84 K
Beta1.0-0.15
Market Capitalization661.17 M19.03 B
Total Asset276.25 M29.47 B
Retained Earnings(271.68 M)9.33 B
Working Capital17.07 M1.48 B
Current Asset21.29 M9.34 B
   Payment of 73678 shares by Brian Lenz of Adma Biologics subject to Rule 16b-3 [view details]

ADMA Biologics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ADMA Biologics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About ADMA Biologics Buy or Sell Advice

When is the right time to buy or sell ADMA Biologics? Buying financial instruments such as ADMA Biologics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Receivables3.47 M13.24 M28.58 M30.83 M
Inventories53.06 M81.54 M124.72 M134.57 M

Use Investing Ideas to Build Portfolios

In addition to having ADMA Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Education Thematic Idea Now

Education
Education Theme
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
View All  Next Launch
Please continue to ADMA Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
661.2 M
Quarterly Revenue Growth YOY
0.99
Return On Assets
(0.11) 
Return On Equity
(0.69) 
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.